S&P 500   3,011.31 (+0.15%)
DOW   26,887.53 (+0.22%)
QQQ   193.10 (-0.15%)
AAPL   241.47 (+0.40%)
FB   184.77 (-2.63%)
MSFT   138.03 (-0.29%)
GOOGL   1,243.27 (-0.08%)
AMZN   1,773.74 (-0.67%)
CGC   20.84 (+2.41%)
NVDA   196.95 (+0.48%)
MU   45.24 (+0.04%)
AMD   31.82 (-0.66%)
T   38.24 (+0.03%)
ACB   3.60 (-2.44%)
NFLX   268.93 (-3.28%)
BAC   31.30 (+0.90%)
GILD   66.00 (+1.21%)
DIS   132.89 (+2.02%)
S&P 500   3,011.31 (+0.15%)
DOW   26,887.53 (+0.22%)
QQQ   193.10 (-0.15%)
AAPL   241.47 (+0.40%)
FB   184.77 (-2.63%)
MSFT   138.03 (-0.29%)
GOOGL   1,243.27 (-0.08%)
AMZN   1,773.74 (-0.67%)
CGC   20.84 (+2.41%)
NVDA   196.95 (+0.48%)
MU   45.24 (+0.04%)
AMD   31.82 (-0.66%)
T   38.24 (+0.03%)
ACB   3.60 (-2.44%)
NFLX   268.93 (-3.28%)
BAC   31.30 (+0.90%)
GILD   66.00 (+1.21%)
DIS   132.89 (+2.02%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Melinta TherapeuticsInnovate BiopharmaceuticalsAclaris TherapeuticsLeap TherapeuticsVIVUS
SymbolNASDAQ:MLNTNASDAQ:INNTNASDAQ:ACRSNASDAQ:LPTXNASDAQ:VVUS
Price Information
Current Price$4.50$0.99$1.57$1.17$4.08
52 Week RangeHoldBuyBuyBuyN/A
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyN/A
Consensus Price Target$32.10$10.00$9.00$9.00N/A
% Upside from Price Target613.33% upside910.10% upside473.25% upside669.23% upsideN/A
Trade Information
Market Cap$62.98 million$38.04 million$66.60 million$27.41 million$45.60 million
Beta4.54-2.420.832.471.78
Average Volume445,102111,3991,423,381160,41950,809
Sales & Book Value
Annual Revenue$96.43 million$4.07 million$10.09 millionN/A$65.06 million
Price / Sales0.648.736.44N/A0.67
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$16.96 per share($0.14) per share$5.26 per share$0.62 per share($3.77) per share
Price / Book0.27-7.070.30N/A-1.08
Profitability
Net Income$-157,190,000.00$-24,160,000.00$-132,740,000.00$-23,140,000.00$-36,950,000.00
EPS($17.72)($0.98)($4.03)($2.51)($3.48)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-135.23%N/A-979.65%N/A-37.95%
Return on Equity (ROE)-60.39%-1,558.03%-81.40%-297.79%N/A
Return on Assets (ROA)-24.46%-123.02%-60.11%-141.13%-9.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.11%N/A0.22%0.07%N/A
Current Ratio1.18%1.51%3.23%1.99%0.69%
Quick Ratio0.87%1.51%3.22%1.99%0.56%
Ownership Information
Institutional Ownership Percentage19.45%9.76%86.10%10.84%14.78%
Insider Ownership Percentage60.30%7.90%14.80%36.10%12.00%
Miscellaneous
Employees29081692357
Shares Outstanding13.75 million35.88 million41.37 million24.04 million10.64 million
Next Earnings Date11/6/2019 (Estimated)11/12/2019 (Estimated)11/5/2019 (Estimated)11/8/2019 (Estimated)11/7/2019 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
 Melinta TherapeuticsInnovate BiopharmaceuticalsAclaris TherapeuticsLeap TherapeuticsVIVUS

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel